Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-07921585 + sasanlimab
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Fc Fusion Proteins → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
PF-07921585 + sasanlimab is an investigational combination therapy under development by Pfizer for the treatment of advanced solid tumors, including non-small cell lung cancer, colorectal cancer, bladder cancer, melanoma, kidney cancer, and head and neck cancer. PF-07921585 is an interleukin-12 (IL-12) mutein designed to stimulate anti-tumor immunity by activating the IL-12 receptor, while sasanlimab is a monoclonal antibody that inhibits the programmed cell death protein 1 (PD-1) pathway, functioning as an immune checkpoint inhibitor. The combination aims to enhance anti-tumor responses by targeting both innate and adaptive immune pathways. PF-07921585 is administered intravenously or subcutaneously; sasanlimab is administered subcutaneously. Both are in early to mid-phase clinical trials as monotherapies and in combination, primarily for oncology indications[1][2][4].
- Other names
- PF-07921585 + sasanlimab
02
Targets
IL-12R (Interleukin-12 receptor)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on PF-07921585 + sasanlimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-07921585 + sasanlimab.